CTXR - Citius Pharmaceuticals

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
• Citius Pharma to spinoff its immunotherapy I/ONTAK into a new publicly-traded company
• Citius Pharmaceuticals GAAP EPS of -$0.05 beats by $0.02
• Citius to add overseas sites to Phase 3 trial for antibiotic lock therapy
• Citius Pharma realigns management to support commercialization of two late-stage products
• Citius stock soars 16% as I/ONTAK seen to equal discontinued cancer drug in phase 3 trial
• Citius Pharmaceuticals GAAP EPS of -$0.06 in-line
• Citius Pharmaceuticals reports FY results
• Citius Pharmaceuticals acquires license for lymphoma treatment E7777 from Dr. Reddy's
• Citius Pharmaceuticals reports Q3 results
• Provention Bio among healthcare gainers; Arrowhead Pharmaceuticals and Citius Pharma among losers
• Alterity Therapeutics, TRxADE HEALTH leads healthcare gainers; Citius Pharmaceuticals, Aligos Therapeutics among major losers
• Citius Pharma stock tanks 16% despite "positive" DMC recommendation to continue late-stage Mino-Lok trial
• Citius Pharmaceuticals adds John Laffey to scientific advisory board
• Citius Pharmaceuticals provides late-stage Mino-Lok trial timeline update
• Citius Pharmaceuticals set to join Russell 2000 Index
• Citius Pharmaceuticals EPS beats by $0.05
• Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
• Citius Pharma slips 8% on capital raise
• Citius Pharma to raise $20M through share sale